Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial

Nazia Raja-Khan, Allen Kunselman, Cynthia S. Hogeman, Christy M. Stetter, Laurence Demers, Richard Legro

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To determine the effects of statins on vascular function, inflammation, and androgen levels in women with polycystic ovary syndrome (PCOS), we randomized 20 women with PCOS who had low-density lipoprotein cholesterol levels >100 mg/dL to atorvastatin (40 mg/day) or placebo for 6 weeks and found that atorvastatin reduced androgen levels, biomarkers of inflammation, and blood pressure; increased insulin levels and brachial artery conductance during reactive hyperemia; and failed to improve brachial artery flow-mediated dilation. We conclude that until additional studies demonstrate a clear risk-to-benefit ratio favoring statin therapy in PCOS, statins should only be used in women with PCOS who meet current indications for statin treatment.

Original languageEnglish (US)
Pages (from-to)1849-1852
Number of pages4
JournalFertility and sterility
Volume95
Issue number5
DOIs
StatePublished - Apr 1 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Polycystic Ovary Syndrome
Androgens
Blood Vessels
Randomized Controlled Trials
Placebos
Inflammation
Brachial Artery
Hyperemia
LDL Cholesterol
Dilatation
Biomarkers
Insulin
Blood Pressure
Atorvastatin Calcium
Therapeutics

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

@article{91c593f0309a4d95b056582c10d5a8a2,
title = "Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial",
abstract = "To determine the effects of statins on vascular function, inflammation, and androgen levels in women with polycystic ovary syndrome (PCOS), we randomized 20 women with PCOS who had low-density lipoprotein cholesterol levels >100 mg/dL to atorvastatin (40 mg/day) or placebo for 6 weeks and found that atorvastatin reduced androgen levels, biomarkers of inflammation, and blood pressure; increased insulin levels and brachial artery conductance during reactive hyperemia; and failed to improve brachial artery flow-mediated dilation. We conclude that until additional studies demonstrate a clear risk-to-benefit ratio favoring statin therapy in PCOS, statins should only be used in women with PCOS who meet current indications for statin treatment.",
author = "Nazia Raja-Khan and Allen Kunselman and Hogeman, {Cynthia S.} and Stetter, {Christy M.} and Laurence Demers and Richard Legro",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.fertnstert.2010.11.040",
language = "English (US)",
volume = "95",
pages = "1849--1852",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome : A double-blind, randomized, placebo-controlled trial. / Raja-Khan, Nazia; Kunselman, Allen; Hogeman, Cynthia S.; Stetter, Christy M.; Demers, Laurence; Legro, Richard.

In: Fertility and sterility, Vol. 95, No. 5, 01.04.2011, p. 1849-1852.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome

T2 - A double-blind, randomized, placebo-controlled trial

AU - Raja-Khan, Nazia

AU - Kunselman, Allen

AU - Hogeman, Cynthia S.

AU - Stetter, Christy M.

AU - Demers, Laurence

AU - Legro, Richard

PY - 2011/4/1

Y1 - 2011/4/1

N2 - To determine the effects of statins on vascular function, inflammation, and androgen levels in women with polycystic ovary syndrome (PCOS), we randomized 20 women with PCOS who had low-density lipoprotein cholesterol levels >100 mg/dL to atorvastatin (40 mg/day) or placebo for 6 weeks and found that atorvastatin reduced androgen levels, biomarkers of inflammation, and blood pressure; increased insulin levels and brachial artery conductance during reactive hyperemia; and failed to improve brachial artery flow-mediated dilation. We conclude that until additional studies demonstrate a clear risk-to-benefit ratio favoring statin therapy in PCOS, statins should only be used in women with PCOS who meet current indications for statin treatment.

AB - To determine the effects of statins on vascular function, inflammation, and androgen levels in women with polycystic ovary syndrome (PCOS), we randomized 20 women with PCOS who had low-density lipoprotein cholesterol levels >100 mg/dL to atorvastatin (40 mg/day) or placebo for 6 weeks and found that atorvastatin reduced androgen levels, biomarkers of inflammation, and blood pressure; increased insulin levels and brachial artery conductance during reactive hyperemia; and failed to improve brachial artery flow-mediated dilation. We conclude that until additional studies demonstrate a clear risk-to-benefit ratio favoring statin therapy in PCOS, statins should only be used in women with PCOS who meet current indications for statin treatment.

UR - http://www.scopus.com/inward/record.url?scp=79952992901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952992901&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2010.11.040

DO - 10.1016/j.fertnstert.2010.11.040

M3 - Article

C2 - 21144505

AN - SCOPUS:79952992901

VL - 95

SP - 1849

EP - 1852

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -